Breaking News
Get 50% Off 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

Prime Medicine Inc (PRME)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Prime Medicine's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.040 +0.300    +8.02%
01/08 - Closed. Currency in USD
Pre Market
4.200
+0.160
+3.960%
10:40:56 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 4,744,561
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 3.510 - 4.070
Prime Medicine 4.040 +0.300 +8.02%

Prime Medicine Inc Company Profile

 
Get an in-depth profile of Prime Medicine Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

214

Equity Type

ORD

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 60 First Street
Cambridge, 02141
United States
Phone 617 465 0013
Fax -

Top Executives

Name Age Since Title
Gerald Schwank - 2023 Member of Scientific Advisory Board
Agnieszka Czechowicz - 2022 Member of Scientific Advisory Board
Shengdar Q. Tsai - 2022 Member of Scientific Advisory Board
Muthiah Manoharan 72 2022 Member of Scientific Advisory Board
Jay Shendure - 2022 Member of Scientific Advisory Board
Jeffrey D. Marrazzo 46 2023 Executive Chair
Samuel H. Sternberg - 2022 Member of Scientific Advisory Board
Michael A. Kelly 68 2021 Independent Director
Anastasia Khvorova 56 2022 Member of Scientific Advisory Board
Robert Taylor Nelsen 63 2020 Independent Director
Wendy K. Chung 56 2021 Independent Director
Kaye I. Foster-Cheek 65 2021 Independent Director
Thomas J. Cahill 38 2021 Independent Director
David P. Schenkein 68 2019 Independent Director
Ben Kleinstiver - 2022 Member of Scientific Advisory Board
Yvonne Y. Chen - 2022 Member of Scientific Advisory Board
Guangping Gao - 2022 Member of Scientific Advisory Board
Eric N. Olson - - Member of Scientific Advisory Board
James Haber - 2022 Member of Scientific Advisory Board
Allan Reine 50 2024 CEO & Director
David R. Liu - 2022 Co-Founder & Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PRME Comments

Write your thoughts about Prime Medicine Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email